HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Stress Drives Anxiety-Reducing Supplement Sales Up 79% In US Since 2018

Executive Summary

Sales for anxiety/stress relief dietary supplements in 2020 grew 79% from 2018, eclipsing growth of 22% for general herbal supplements during the same comparison period. Stress-relief supplements including St. John’s wart, ashwagandha and cannabinoids continue to grow in popularity.

You may also be interested in...



US Supplement Market Regulation: Depression Claim, Undisclosed Drug, COVID Tincture

FDA warns 10 businesses they’re marketing unapproved and misbranded drugs by making claims for supplements to treat depression. Supplement also found with one of, if not the most common violations in the US supplement market: it contained an undisclosed ED drug.

US Import Alert Stops Some, Not All Contaminated Sanitizers; Recalls Mount Due To Methanol

FDA asks two Mexican manufacturers for batch and supplier data on the products found to contain mostly methanol instead of ethanol. Its The FDA’s recall records still are frequently updated with announcements of additional recalls of OTC sanitizers due to the presence of methanol.

COVID-19 Test Kit’s Use Of US FDA Logo With ‘Clinical Trial Number’ Fails Regulatory Test

Anytime COVID Test marketed home-use test without FDA approval or EUA and promoted it with an FDA logo and a “clinical trial number.” Warning letter says “your presentation conveys the misimpression that the product has been approved, cleared, authorized, endorsed or otherwise evaluated by FDA.”

Topics

UsernamePublicRestriction

Register

RS151287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel